Terns Pharmaceuticals Number Of Shares Shorted vs. Current Ratio
| TERN Stock | USD 6.24 0.10 1.58% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.39 | 0.44 |
|
|
For Terns Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Terns Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Terns Pharmaceuticals utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Terns Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Terns Pharmaceuticals over time as well as its relative position and ranking within its peers.
Terns |
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Terns Pharmaceuticals. If investors know Terns will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Terns Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.18) | Revenue Per Share 0.035 | Return On Assets (0.19) | Return On Equity (0.28) |
The market value of Terns Pharmaceuticals is measured differently than its book value, which is the value of Terns that is recorded on the company's balance sheet. Investors also form their own opinion of Terns Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Terns Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Terns Pharmaceuticals' market value can be influenced by many factors that don't directly affect Terns Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Terns Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Terns Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Terns Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Terns Pharmaceuticals Current Ratio vs. Number Of Shares Shorted Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Terns Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Terns Pharmaceuticals value to that of its competitors to determine the firm's financial worth. Terns Pharmaceuticals is rated fourth in number of shares shorted category among its peers. It is rated third in current ratio category among its peers . The ratio of Number Of Shares Shorted to Current Ratio for Terns Pharmaceuticals is about 168,577 . At this time, Terns Pharmaceuticals' Current Ratio is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Terns Pharmaceuticals' earnings, one of the primary drivers of an investment's value.Terns Current Ratio vs. Number Of Shares Shorted
Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.
Terns Pharmaceuticals |
| = | 3.98 M |
If a large number of investors decide to short sell an equity instrument within a small period of time, their combined action can significantly affect the price of the stock.
Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
Terns Pharmaceuticals |
| = | 23.59 X |
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).
Terns Current Ratio Comparison
Terns Pharmaceuticals is currently under evaluation in current ratio category among its peers.
Terns Pharmaceuticals Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Terns Pharmaceuticals, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Terns Pharmaceuticals will eventually generate negative long term returns. The profitability progress is the general direction of Terns Pharmaceuticals' change in net profit over the period of time. It can combine multiple indicators of Terns Pharmaceuticals, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | -19 K | -19.9 K | |
| Net Interest Income | 12.9 M | 13.5 M | |
| Interest Income | 12.9 M | 13.5 M | |
| Operating Income | -102.6 M | -97.4 M | |
| Net Loss | -90.2 M | -85.7 M | |
| Income Before Tax | -90 M | -85.5 M | |
| Total Other Income Expense Net | 12.6 M | 13.2 M | |
| Net Loss | -54.3 M | -57 M | |
| Net Loss | -90.2 M | -85.7 M | |
| Income Tax Expense | 239 K | 335.7 K | |
| Non Operating Income Net Other | 1.8 M | 1.6 M | |
| Change To Netincome | 12.4 M | 13 M | |
| Net Loss | (1.27) | (1.33) | |
| Income Quality | 0.75 | 0.94 | |
| Net Income Per E B T | 1.00 | 0.80 |
Terns Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Terns Pharmaceuticals. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Terns Pharmaceuticals position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Terns Pharmaceuticals' important profitability drivers and their relationship over time.
Use Terns Pharmaceuticals in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Terns Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Terns Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Terns Pharmaceuticals Pair Trading
Terns Pharmaceuticals Pair Trading Analysis
The ability to find closely correlated positions to Terns Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Terns Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Terns Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Terns Pharmaceuticals to buy it.
The correlation of Terns Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Terns Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Terns Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Terns Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Terns Pharmaceuticals position
In addition to having Terns Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Crypto And Gold Thematic Idea Now
Crypto And Gold
Assets that cancel away each other volatility by providing diversification into gold investment combined with digital assets. The Crypto And Gold theme has 54 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Crypto And Gold Theme or any other thematic opportunities.
| View All Next | Launch |
Check out World Market Map. To learn how to invest in Terns Stock, please use our How to Invest in Terns Pharmaceuticals guide.You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
To fully project Terns Pharmaceuticals' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Terns Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Terns Pharmaceuticals' income statement, its balance sheet, and the statement of cash flows.